Last reviewed · How we verify
NCT06598761
Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC
trial testing Immunotherapy+radiotherapy in Ureter Cancer in 60 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Peking University First Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 January 2022 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 August 2027 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Immunotherapy+radiotherapy
- surveillance alone
Conditions studied
- Ureter Cancer — all drugs for Ureter Cancer →
- Renal Pelvic Carcinoma — all drugs for Renal Pelvic Carcinoma →
- Advanced Urothelial Carcinoma — all drugs for Advanced Urothelial Carcinoma →
Sponsor
Peking University First Hospital
Who can join
Adults 18 to 80, any sex, with Ureter Cancer or Renal Pelvic Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective cohort study to analyse the safety and efficacy of postoperative adjuvant radiotherapy combined with immunotherapy versus surgery alone group of UTUC patients with T3-4 stages or lymph nodes metastasis(N+) status.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06598761
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ureter Cancer
Currently open trials in the same condition.
- NCT06349668 — Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery · Phase 3 · recruiting
- NCT06652022 — Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs · NA · recruiting
Other Peking University First Hospital trials
Trials by the same sponsor.
- NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
- NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
- NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
- NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
- NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06598761 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
- Last refreshed: 5 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06598761.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing